Ultimovacs enters the Oslo Stock Exchange
Oslo Cancer Cluster member Ultimovacs entered the Oslo Stock Exchange on Monday 3 June 2019.
Sofia Lindén is responsible for producing the content for digital communications in the cluster, including articles, photographs and videos for the websites and social media platforms.
She has previously worked at the Nordic publishing company Orage as Swedish Print Editor and Digital Project Manager. She also holds a master degree in International Journalism from City University London. Find out more about Sofia by visiting her LinkedIn.
Oslo Cancer Cluster member Ultimovacs entered the Oslo Stock Exchange on Monday 3 June 2019.
Nordic Nanovector raises NOK 225 million in private placements, has Phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company.
Biobanks – the powerful tools in cancer research you may have never heard of.
We asked four MBA students from Cambridge University to evaluate how patient recruitment practices in Norway can be improved.
Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and medicines.
We are a national non-profit member organization with about 90 members. Our members are Norwegian and international companies, research and financial institutions, university hospitals and organizations – all working in the cancer field.